Nektar Therapeutics has recruited Bharatt Chowrira as chief operating officer and head of its PEGylation business unit. In this capacity he will be responsible for overseeing and managing all aspects of the PEGylation business, including research and manufacturing. Chowrira has previously held senior positions at Merck & Co and Sirna Therapeutics, which have utilised his knowledge of molecular biology, business strategy and intellectual property. Mary Haak-Frendscho has been appointed as president and chief scientific officer of Takeda San Francisco, taking responsibility for research and preclinical development, process development studies and operations for antibody therapeutics. Haak-Frendscho has over 17 years of pharmaceutical and biotechnology experience, at Genentech, Abgenix and most recently, at XOMA, where she served as chief science officer and vice president, preclinical research and development. Altus Pharmaceuticals has named Georges Gemayel as its CEO and to its board of directors. Gemayel was previously executive vice president and a company officer at Genzyme and also held posts at Hoffman-La Roche for 16 years. Keith Dovel has been promoted to the position of president and chief operating officer at Plymouth Printing, a manufacturer of printed packaging components for the pharmaceutical and healthcare markets. Dovel has been vice-president at Plymouth since January 2006, having accumulated over 30 years of managerial experience in pharmaceutical printing operations. In an attempt to expand its presence in contract manufacturing and packaging Norwich Pharmaceuticals has made three new appointments. Douglas Drysdale has joined the company as CEO, having previously held posts at Alpharma and Forest Laboratories. During his time in the industry Drysdale has been involved in over 100 pharmaceutical and biotech transactions. In addition Thomas Salus and Robert Klehr have been appointed with a remit for new business development, an area they most recently covered for Glatt and DPT Laboratories, respectively. Altus Pharmaceuticals has appointed Georges Gemayel as its new CEO. Gemayel was previously executive vice president at Genzyme where he had worked since 2003. Gerard Picot has been appointed as vice president, global regulatory affairs at Ipsen. In this capacity Picot will be responsible for enhancing the regulatory position of Ipsen and its products. Picot has over 25 years experience in the pharmaceutical industry at companies including Laboratoires Fournier and Bristol-Myers Squibb. Setaram, a manufacturer and supplier of thermal analysers, calorimeters, and high pressure mass spectroscopy instruments, has appointed Bruce Jamieson as CEO. Jamieson has over 20 years of experience in the life sciences and laboratory automation industries including stints at Labcyte and Argonaut. GlaxoSmithKline has named Roger Scarlett-Smith as president of its North America division headquartered near Pittsburgh. The previous president George Quesnelle has been appointed as president of global switch and strategic growth projects. Secure Symbology, a provider of anti-counterfeiting tools has appointed Andre Schultz to lead its serialisation and RFID integration team. Schultz previously worked for Systech in the serialization and RFID arena and also spent several years at Siemens, working on RFID when it was still in its infancy.